

IN OTHER NEWS

2007 PHYSICIAN QUALITY REPORTING INITIATIVE (PQRI) TOOL KIT – EIGHT STEPS FOR SUCCESS

This Tool Kit includes valuable resources to assist eligible professionals in the successful integration of PQRI measurement into their practice. CMS suggests that eligible professionals review and discuss the following materials with their staff. The Tool Kit has been expanded to include the newly released 2007 PQRI Measure Finder Tool.

A link to the **2007 PQRI Tool Kit – Eight Steps for Success** can be found on OA's website at www.oagpo.com under News and Events on the homepage.



INFORMATION ABOUT CONCURRENT USE OF CALCIUM/MAGNESIUM WITH ELOXATIN® (OXALIPLATIN INJECTION)

From a Recent Unplanned Interim Analysis of Data from a Phase IV Study (CONcePT)

An unplanned interim analysis of data from a Phase IV study by the Data Monitoring Committee indicated that calcium/magnesium (Ca/Mg) infusions, administered to reduce or prevent oxaliplatin-associated neurological adverse events, may be associated with a reduced response rate to FOLFOX/Bevacizumab treatment in the pooled population of patients receiving either the conventional or the intermittent schedule of Oxaliplatin. Sanofi-aventis closed the study and intends to promptly collect and analyze the study data and to present the findings when the analysis is complete.

Pending more definitive information from this study, healthcare providers should weigh the perceived beneficial effect on neuropathy of initiated or continuing Ca/Mg infusions in patients on Oxaliplatin against the possibility of diminished benefit of chemotherapy.

If you have questions, please contact Sanofi Aventis Medical Information Services at **800-633-1610**.

Please visit OA's website at www.oagpo.com under News and Events on the homepage for more information on the CONcePT study.

